Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.

Todd T BrownKrista YuhasKenneth H MayerRaphael J LandovitzMark A MarzinkeCraig W HendrixYing Q ChenKaren L KlingmanWairimu ChegeMarybeth B MccauleyRoy M GulickTimothy J Wilkin

Published in: The Journal of antimicrobial chemotherapy (2021)

Tenofovir disoproxil fumarate-containing PrEP was associated with significantly greater bone loss compared with maraviroc ± emtricitabine PrEP at the hip, but not the LS. The BMD changes at the hip were similar in magnitude in men and women.

Keyphrases

bone loss
men who have sex with men
total hip arthroplasty
antiretroviral therapy
soft tissue
postmenopausal women